Panbela Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.19%162.940.7%$1094.46m
MRKMerck & Co., Inc. 0.78%76.170.7%$1032.73m
LLYEli Lilly & Co. 6.31%230.801.1%$953.07m
PFEPfizer Inc. 0.27%39.160.9%$928.70m
ABBVAbbVie, Inc. 0.39%114.441.9%$720.94m
BMYBristol-Myers Squibb Co. 0.74%65.751.0%$629.63m
AZNAstraZeneca Plc 0.75%58.421.2%$392.39m
OGN 0.53%29.660.0%$270.10m
ORPHOrphazyme A/S 6.99%7.960.0%$225.36m
GSKGlaxoSmithKline Plc -0.72%39.570.2%$182.10m
NVSNovartis AG 0.12%92.500.2%$180.35m
NOVNNovan, Inc. 0.19%10.515.8%$132.69m
CVACCureVac NV 4.37%59.400.0%$115.84m
CNSTConstellation Pharmaceuticals, Inc. 0.18%33.820.0%$110.98m
RPRXRoyalty Pharma Plc 2.57%43.280.2%$106.65m

Company Profile

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.